Efficacy of a Combination of Epoetin and Iron Supplements in the Treatment of Widespread Brights Anemia in Patients on Hemodialysis
Annotatsiya
Abstract: Bright's anemia, a common complication in patients undergoing hemodialysis, significantly impacts their quality of life and clinical outcomes. This study evaluates the efficacy of a combined treatment regimen of epoetin and iron supplements in managing widespread Bright's anemia in hemodialysis patients. A total of 150 patients with confirmed Bright's anemia were enrolled and randomly assigned to receive either epoetin alone (control group) or a combination of epoetin and iron supplements (treatment group) over a 12-week period. Hemoglobin levels, hematocrit values, and quality of life metrics were assessed at baseline and at the end of the study. Results indicated a statistically significant improvement in hemoglobin and hematocrit levels in the treatment group compared to the control group (p < 0.01). Additionally, patients receiving the combined treatment reported better quality of life scores and fewer anemia-related symptoms. These findings suggest that the combination of epoetin and iron supplements is more effective in treating Bright's anemia in hemodialysis patients than epoetin alone, potentially offering a superior therapeutic approach for this population.